Moreover, the limited tumor-suppressive activity of BRCA1 and BRCA2 in sporadic breast and ovarian cancers may result from the relatively late occurrence of somatic mutations, in contrast to inherited mutations, which are present throughout development and provide more time for oncogenic processes to accumulate. The gene discussed is BRCA2; the disease is neoplasm.